Original Article

You have full text access to this OnlineOpen article

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia†

  1. Mark L. Heaney MD, PhD1,‡,*,
  2. Edmond L. Toy PhD2,
  3. Francis Vekeman MA3,
  4. François Laliberté MA3,
  5. Bree L. Dority PhD2,
  6. Daniel Perlman BA2,
  7. Victoria Barghout MSPH4,
  8. Mei Sheng Duh MPH, ScD5

Article first published online: 27 JUL 2009

DOI: 10.1002/cncr.24535

Issue

Cancer

Cancer

Volume 115, Issue 20, pages 4839–4848, 15 October 2009

Additional Information

How to Cite

Heaney, M. L., Toy, E. L., Vekeman, F., Laliberté, F., Dority, B. L., Perlman, D., Barghout, V. and Duh, M. S. (2009), Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. Cancer, 115: 4839–4848. doi: 10.1002/cncr.24535

Author Information

  1. 1

    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

  2. 2

    Analysis Group, Inc, Lakewood, Colorado

  3. 3

    Analysis Group, Inc, Montreal, Quebec, Canada

  4. 4

    U.S. Health Economics and Outcomes Research Division, Bayer HealthCare Pharmaceuticals, Inc, Wayne, New Jersey

  5. 5

    Analysis Group, Inc, Boston, Massachusetts

  1. ‡

    Fax: (212) 772-8550

*Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065

  1. †

    Presented in part at the 50th Annual Meeting and Exposition of the American Society of Hematology, San Francisco, California, December 6-9, 2008.

Publication History

  1. Issue published online: 5 OCT 2009
  2. Article first published online: 27 JUL 2009
  3. Manuscript Accepted: 1 MAY 2009
  4. Manuscript Revised: 19 MAR 2009
  5. Manuscript Received: 22 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (158K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Derek Weycker, Jennifer Malin, Rich Barron, John Edelsberg, Alex Kartashov, Gerry Oster, Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim as Prophylaxis Against Hospitalization for Neutropenic Complications in Patients With Cancer Receiving Chemotherapy, American Journal of Clinical Oncology, 2012, 35, 3, 267

    CrossRef

  2. 2
    Panayiotis D. Ziakas, Irene S. Kourbeti, Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide?, Clinical Transplantation, 2012, 26, 1
    Direct Link:
  3. 3
    Bradford R. Hirsch, Gary H. Lyman, Pharmacoeconomics of the Myeloid Growth Factors, PharmacoEconomics, 2012, 30, 6, 497

    CrossRef

  4. 4
    Derek Weycker, John Edelsberg, Alex Kartashov, Rich Barron, Gary Lyman, Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer, Chemotherapy, 2012, 58, 1, 8

    CrossRef

  5. 5
    Andrea V. Page, W. Conrad Liles, Colony-Stimulating Factors in the Prevention and Management of Infectious Diseases, Infectious Disease Clinics of North America, 2011, 25, 4, 803

    CrossRef

  6. 6
    Derek Weycker, Richard L. Barron, Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia, Cancer, 2010, 116, 12
    Direct Link:
  7. 7
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2010, 19, 4
    Direct Link:
  8. 8
    Mark L. Heaney, Edmond L. Toy, Francis Vekeman, Reply to Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia, Cancer, 2010, 116, 12
    Direct Link:
View Full Article (HTML) Get PDF (158K)